ROR1標的治療市場：標的発現プロファイル、薬物モダリティの安全性と有効性、パイプラインレビュー、および競合情勢分析

当レポートでは、ROR1標的治療市場について調査し、市場の概要とともに、ROR1標的治療の臨床動向、適応症と患者動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

頻繁な略語

第0章 エグゼクティブサマリー

第1章 標的の背景：構造と機能

第2章 標的抗原発現プロファイル

• 血液悪性腫瘍
• さまざまな固形腫瘍
• 肺癌
• 膵臓癌
• 大腸癌
• 乳癌
• 卵巣癌

第3章 ROR1標的治療薬候補の前臨床安全性

第4章 ROR1標的薬物モダリティの臨床経験

第5章 臨床適応症と患者集団

• 慢性リンパ性白血病
• マントル細胞リンパ腫
• びまん性大細胞型B細胞リンパ腫
• トリプルネガティブ乳癌

第6章 競合情勢と薬物モダリティ

• ROR1標的抗体薬物複合体
• T細胞エンゲージング抗ROR1抗体
• ROR1標的CART細胞とNK細胞別養子細胞療法
• ROR1小分子阻害剤

第7章 薬物および細胞治療の候補薬プロファイル

• 裸の抗体
• 抗体薬物複合体
• T細胞が関与する二重特異性抗体
• CART細胞とNK細胞
• 小分子阻害剤

第8章 企業プロファイル

第9章 参考文献

List of Tables

• Table 1: Overview of the Number of Cases of ROR1 Overexpression in Hematologic Malignancies
• Table 2: Overview of the Number of Cases of ROR1 Overexpression in Solid Tumors
• Table 3: Lead and Up-Side Indications of Clinical Studies with ROR1-Targeted Therapy Candidates
• Table 4: Overview of Number and R&D Stage of ROR1-Targeted Drug Modalities
• Table 5: Pipeline of ROR1-Targeted Antibody-Drug Conjugates in Development
• Table 6: Pipeline of T-Cell Engaging ROR1-Targeted Antibodies
• Table 7: Pipeline of ROR1-Targeted CAR T-Cells and NK Cells
• Table 8: NovalGen's ROR1-Targeted Drug Modality Pipeline

This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as a tumor-specific target for cancer therapy based on its expression profile and preclinical and clinical safety and efficacy data of the various drug modalities employed for discovery and development of ROR1-targeted therapy candidates.

The report has identified the players in the field and presents a competitive landscape analysis of stakeholders and a pipeline review based on the specific profiles of drug candidates and companies active in the field. The report includes information about business transaction in the field, such as acquisitions, partnerships & collaborations and licensing deals. Furthermore, the financial background and situation of the key players is described.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a type I transmembrane protein that is physiologically expressed in early embryogenesis and plays a critical role in organogenesis. Expression of ROR1 attenuates rapidly after embryonic development, becoming virtually undetectable on post-partem tissues, with the exception of a few B cell precursors. In contrast, ROR1 is expressed on a variety of cancers, particularly those that are less differentiated, and is associated with early relapse after therapy or metastasis.

Because of its tumor-specific expression and potential functional significance, ROR1 has become of interest as a target for various drug modalities, especially with enhanced effector function. The most advanced molecules is currently being evaluated in potentially registrational phase II/III studies, but the majority of programs are in late preclinical and early clinical development, thus still offering opportunities for improvements.

This report is based information retrieved from proprietary database, clinical trial registries, abstracts, presentations and posters from scientific meetings as well as full publications, from company websites, press releases, SEC filings, investor and R&D presentations. The report was prepared in May/June of 2022 and was released on June 16, 2022.

What will you find in the report:

• The scientific rationale for ROR1-targeted therapies based on target characteristics and its differential expression profile;

• Preclinical safety of ROR1-targeted therapy candidates;

• Clinical experience and proof-of-concept with ROR1-targeted drug modalities;

• Clinical indications suitable for development of ROR1-targeted therapies and their patient populations;

• The competitive landscape of ROR1-targeted drug modalities in development;

• Specific profiles of ROR1-targeted drug modalities; and

• Profiles of companies active in the development of anti-ROR1 therapy candidates.

Table of Contents

Frequent Abbreviations

0. Executive Summary

1. Target Background: Structure & Function

2. Target Antigen Expression Profile

• 2.1. Hematologic Malignancies
• 2.2. Various Solid Tumors
• 2.3. Lung Cancer
• 2.4. Pancreatic Cancer
• 2.5. Colorectal Cancer
• 2.6. Breast Cancer
• 2.7. Ovarian Cancer

3. Preclinical Safety of ROR1-Targeted Therapy Candidates

4. Clinical Experience with ROR1-Targeted Drug Modalities

5. Clinical Indications & Patient Populations

• 5.1. Chronic Lymphocytic Leukemia
• 5.2. Mantle Cell Lymphoma
• 5.3. Diffuse Large B-Cell Lymphoma
• 5.4. Triple Negative Breast Cancer

6. Competitive Landscape & Drug Modalities

• 6.1. ROR1-Targeted Antibody Drug Conjugates
• 6.2. T-Cell EngagingAnti-ROR1 Antibodies
• 6.3. Adoptive Cell Therapy with ROR1-Targeted CAR T-Cells and NK Cells
• 6.4. ROR1 Small Molecule Inhibitor

7. Drug & Cell Therapy Candidate Profiles

• 7.1. Naked Antibody
• 7.2. Antibody-Drug Conjugates
• 7.3. T-Cell Engaging Bispecific Antibodies
• 7.4. CAR T-Cells & NK Cells
• 7.5. Small Molecule Inhibitor

8. Company Profiles

9. References